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Drug- and noise-related hearing loss are both associated with inflammatory responses
in the inner ear. We propose that intracochlear delivery of a combination of pro-resolving
mediators, specialized proteins and lipids that accelerate the return to homeostasis by
modifying the immune response rather than by inhibiting inflammation, might have a
profound effect on the prevention of sensorineural hearing loss. However, intracochlear
delivery of such agents requires a reliable and effective method to convey them, fully
active, directly to the target cells. The present study provides evidence that extracellular
vesicles (EVs) from auditory HEI-OC1 cells may incorporate significant quantities of
anti-inflammatory drugs, pro-resolving mediators and their polyunsaturated fatty acid
precursors as cargo, and potentially could work as carriers for their intracochlear
delivery. EVs generated by HEI-OC1 cells were divided by size into two fractions, small
(≤150 nm diameter) and large (>150 nm diameter), and loaded with aspirin, lipoxin A4,
resolvin D1, and the polyunsaturated fatty acids (PUFA) arachidonic, eicosapentaenoic,
docosahexanoic, and linoleic. Bottom-up proteomics revealed a differential distribution
of selected proteins between small and large vesicles. Only 17.4% of these proteins
were present in both fractions, whereas 61.5% were unique to smaller vesicles and only
3.7% were exclusively found in the larger ones. Importantly, the pro-resolving protein
mediators Annexin A1 and Galectins 1 and 3 were only detected in small vesicles.
Lipidomic studies, on the other hand, showed that small vesicles contained higher levels
of eicosanoids than large ones and, although all of them incorporated the drugs and
molecules investigated, small vesicles were more efficiently loaded with PUFA and the
large ones with aspirin, LXA4 and resolvin D1. Importantly, our data indicate that the
vesicles contain all necessary enzymatic components for the de novo generation of
eicosanoids from fatty acid precursors, including pro-inflammatory agents, suggesting
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that their cargo should be carefully tailored to avoid interference with their therapeutic
purpose. Altogether, these results support the idea that both small and large EVs from
auditory HEI-OC1 cells could be used as nanocarriers for anti-inflammatory drugs and
pro-resolving mediators.
Keywords: extracellular vesicles, HEI-OC1 cells, cochlear inflammation, pro-resolving mediators, drug
nanocarriers, intracochlear drug delivery
INTRODUCTION
Drug- and noise-related hearing loss (DRHL and NRHL,
respectively) are intimately associated with inflammatory
responses in the inner ear (Kaur et al., 2016; Lowthian et al.,
2016; Kalinec et al., 2017; Keithley, 2018). Inflammation,
a normal biological reaction aimed at restoring tissue and
organ functionality and homeostasis, is usually divided
into two phases: initiation and resolution (Kumar et al.,
2014). The initiation of inflammation is characterized by
the up-regulation of pro-inflammatory mediators such as
leukotrienes, prostaglandins, and thromboxanes. When the
inflammatory response peaks, the resolution phase starts.
Inflammatory resolution is an active process achieved mostly
by the action of specialized protein and lipid pro-resolving
mediators (Perretti, 2015; Perretti et al., 2015; Kalinec
et al., 2017). We have recently proposed that stimulation of
pro-resolving pathways associated with cochlear inflammatory
processes could be an important new therapeutic approach for
preventing or ameliorating DRHL and NRHL (Kalinec et al.,
2017), with pro-resolving mediators accelerating the return
to homeostasis by modifying the immune response rather
than by inhibiting inflammation (Dalli and Serhan, 2019). The
successful implementation of this clinical strategy, however,
has several challenges. It requires, for instance, identifying safe
and efficient ways to deliver a combination of pro-resolving
mediators into the cochlea in clinically significant amounts,
without compromising their pharmacokinetics and therapeutic
efficacy and with minimal adverse effects to the host. Thus, this
study was aimed at evaluating whether extracellular vesicles
(EVs) from auditory HEI-OC1 cells could be adequate carriers
for these agents.
Recent studies have shown that packaging drugs into
nanoscale synthetic particles can improve pharmacokinetic
efficiency and therapeutic efficacy (Li et al., 2017; Hao
and Li, 2019). Nonetheless, the use of these drug-loaded
artificial nanoparticles has several disadvantages. For example,
microparticles are usually toxic, they are not stable in biological
environments, assembling them is usually expensive, and they are
not well suited to carry several different drugs simultaneously
(Tang et al., 2012). EVs, in contrast, are naturally adapted
for conveying molecular products from cells that generate
and/or store them to cells that need them. After dexamethasone
treatment, for example, Hensen cells in the guinea pig organ
of Corti accumulate Annexin A1 in their cytoplasm and release
it to the external milieu inside EVs (Kalinec et al., 2009). EVs
have demonstrated promise as a natural delivery system for
combinations of small molecules, proteins, oligonucleotides, and
pharmacological drugs (Robbins and Morelli, 2014; Armstrong
and Stevens, 2018).
EVs have unique advantages as carriers to deliver drugs,
such as their ability to overcome natural biological barriers
and their intrinsic cell targeting properties. Besides, since EVs
are formed from cellular membranes, they are not toxic and
they can be easily manipulated for drug-packaging without
restrictions associated with the physicochemical properties of
drugs. Furthermore, since EVs do not self-replicate, they lack
endogenous tumor-formation potential. Importantly, EVs are
known to be effective for gene and drug delivery, and their
surface and cargo can be engineered to target specific cell types
and to deliver specific components (Marcus and Leonard, 2013).
Moreover, encapsulating some pharmacological drugs into EVs
reduce their toxicity (Tang et al., 2012). Finally, EVs can be
produced in a scaled manner more easily than other therapeutics
(Lai et al., 2019), and because of their small size and scarce
presence of membrane histocompatibility molecules, they carry
a reduced possibility for immune rejection (Reis et al., 2016).
Not less important, intracochlear delivery of EVs loaded with
adeno-associated virus has been already successfully used for
rescuing hearing in a mouse model for hereditary deafness
(György et al., 2017).
EVs are released by cells as self-contained vesicles
encapsulating a small portion of the parent cell cytoplasm.
Cells naturally produce a diverse spectrum of EVs, spanning
from small vesicles of about 50 nm diameter, to large vesicles
up to 10 µm diameter (Mathieu et al., 2019). In the 1980s the
smallest EV, between 50 and 150 nm in diameter, were called
‘‘exosomes,’’ and this term rapidly became the most frequently
used in the EV field (Tkach et al., 2018); the bigger EVs are
known as ‘‘ectosomes’’ or microvesicles. This categorization
is also associated with the specific origin of the vesicles, with
exosomes deriving from the fusion of multivesicular endosomes
with the plasma membrane and microvesicles shedding
directly from the plasma membrane (Colombo et al., 2014).
Independently of their origin, EVs consist of a lipid bilayer,
with integral and surface proteins, and containing in the core
cytoplasmic proteins, lipids, RNAs (including messenger RNA
and microRNAs), DNA, and metabolites (Pinheiro et al., 2018).
They are usually enriched in proteins involved in vesicle genesis
and trafficking, signal transduction, cytoskeleton organization,
antigen presentation and transport, and vesicle targeting to
acceptor cells or to the extracellular matrix (Robbins and
Morelli, 2014). Typically, they also contain proteins belonging
to the tetraspanin protein family such as CD9, CD63 and CD81.
The lipid components of EVs include ceramide (sometimes used
to differentiate them from lysosomes), cholesterol, sphingolipids,
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and phosphoglycerides with long and saturated fatty-acyl chains
(Skotland et al., 2017). Importantly, it has been reported that
EVs naturally contain lipid mediators such as arachidonic
and 12-hydroxyeicosatetraenoic (12-HETE) acids, leukotriene
B4, leukotriene C4, and prostaglandins E2 and J2 (PGE2 and
15d-PGJ2, respectively), as well as lipid-related proteins (Record,
2018). The outer surface of EVs, in turn, is rich in mannose,
polylactosamine, α-2,6 sialic acid, N-linked glycans, lectins,
and galectins (Laulagnier et al., 2004; Yanez-Mo et al., 2015).
Nonetheless, each type of EV has a unique molecular signature
that depends on the parent cell lineage and status (for example,
healthy or pathological), and the stimulus that elicited their
generation and release.
There is no actual proof yet that small EVs have a function
different to that of larger EVs (Tkach et al., 2018; Vagner et al.,
2019), although there is agreement in that these different EV
populations may have different composition even when released
by the same cell type (Mathivanan et al., 2010; Bobrie et al., 2012;
Romancino et al., 2013; Zaborowski et al., 2015; Kowal et al.,
2016; Xu et al., 2016; Vagner et al., 2019). A recent ‘‘consensus’’
publication, co-authored by several prominent scientists in
the field of EVs, stated that ‘‘EVs in the small size range
likely represent vesicles heterogeneous in origin’’ with unknown
portions of exosomes and ectosomes (Mateescu et al., 2017). The
definition of larger EVs is even less precise, with these vesicles
comprising a wide range of membrane-enclosed entities. Indeed,
it is not yet clear how to divide EVs into their relevant subtypes,
or even how many functionally distinct subtypes there are
(Mateescu et al., 2017). In addition, increasing evidence suggests
that different classes of EVs, and different populations within
each class, may harbor unique molecular cargos and have specific
functions (Kowal et al., 2016; Willms et al., 2016; Jeppesen
et al., 2019), clearly indicating the limitations of the size-based
classification. Thus, looking for a better characterization, EVs
have been divided by size into small and large (Tkach et al.,
2018; Vagner et al., 2019). A similar approach was followed
in the present study, with HEI-OC1 EVs divided into two
fractions: small EVs (S-EVs, ≤150 nm in diameter, mostly
exosomes), and large EVs (L-EVs, >150 nm in diameter,
mostly microvesicles).
In summary, endogenously produced EVs are an attractive
drug delivery system mainly because of their small size,
low immunogenicity, absence of toxic effects, and stability
in biological environments (Akao et al., 2011; Fuhrmann
et al., 2015; Wong et al., 2016). In addition, EVs can be
loaded with a designed combination of therapeutic agents and
engineered to target specific cell types (Marcus and Leonard,
2013). Although the actual suitability of EVs for intracochlear
delivery of anti-inflammatory and pro-resolving agents, as well
as its true potential for preventing or alleviating DRHL and
NRHL, will require additional research, confirming them as
a possible safe and efficient nanocarrier for these agents is a
crucial initial step. In the present study, we investigate the
production of EVs by auditory HEI-OC1 cells, characterize
them by proteomics and targeted lipidomics, and evaluate
their capability to incorporate simultaneously anti-inflammatory
and pro-resolving agents in clinically significant quantities.
Our results support the idea that EVs from HEI-OC1 cells
could, indeed, be used as nanocarriers for intracochlear delivery
of drugs and molecular mediators aimed at facilitating the
resolution of inflammatory processes.
MATERIALS AND METHODS
HEI-OC1 Cells
ImmortomouseTM-derived HEI-OC1 cells were grown in
polystyrene cell culture dishes (CellStarTM, Greiner Bio-
One, NC, USA) using DMEM (Gibco, Gaithersburg, MD,
USA) supplemented with 10% FBS (HyClone, Thermo Fisher
Scientific, Waltham, MA, USA), at 33◦C and 10% CO2 as
previously described (Kalinec et al., 2003). At approximately
80% confluence, cells were washed with PBS and fresh cell
culture media supplemented with 10% exosome-depleted FBS
(Cat. #A2720801, Thermo Fisher Scientific, Waltham, MA, USA)
was added. After a further 24 h under the same incubation
conditions, the cell culture media was removed and processed for
EV isolation and characterization.
EVs Isolation and Physical
Characterization
EVs were isolated from the cell culture media using the
commercially available exoEasyTM isolation kit (Qiagen)
following the manufacturer-suggested procedure. Two cell
culture dishes of 100 mm diameter were used per condition,
yielding 16 ml (8 ml/dish) of medium; this medium was
pre-filtered to exclude particles larger than 800 nm, and the
filtrate loaded onto the exoEasyTM spin columns (4 ml per
column, total four columns per condition). After centrifugation
(500× g, 5 min) to remove the residual liquid, 1 ml of elution
buffer was added to each column, and then centrifuged again
for 5 min at 500× g to collect the eluate. Isolated EV samples
(1 ml each in elution buffer per column) were pooled, PBS was
added to obtain a final volume of 200 ml, and then this EV
suspension was filtered by tangential flow with a Sartorious
Vivaflow 50 device with a 200 nm pore size (Cat. #VF05P7.
Sartorious GmbH, Göttingen, Germany). This device allows
the recovery of two fractions: the retained one (L-EVs) with
particles of diameter greater than 200 nm, and the filtrate
(S-EVs) with particles smaller than 200 nm diameter. The
L-EVs fraction was further ultra-filtered and concentrated using
Sartorious Vivaspin 2 with 200 nm pore size (Cat. #VS0271),
and the second filtrate incorporated to the S-EVs fraction.
Next, this combined S-EVs fraction was further ultra-filtered
and concentrated using Sartorious Vivaspin 2 with 100 kDa
pore size (Cat. #VS0241). Using this procedure, the original
EVs obtained from HEI-OC1 cells were separated by size
into two fractions, S-EVs (diameter ≤150 nm) and L-EVs
(diameter >150 nm).
The counting and sizing of EVs in the L-EVs and S-EVs
fractions was accomplished with the Microfluidic Resistive
Pulse Sensing (MRPSTM) technique using a Spectradyne
nCS1TM instrument (Spectradyne LLC, Torrance, CA, USA;
Cleland et al., 2016; Grabarek et al., 2019). This method is
based on monitoring transient changes in electric current,
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also known as the Coulter principle, caused by particles
passing through a narrow orifice (Song et al., 2017). When a
nanoparticle passes through the constriction, it blocks some
of the electrical sensing current, increasing the electrical
resistance of the constriction by an amount proportional to
the nanoparticle volume. Monitoring the electrical resistance
as a function of time thus yields a number of short pulses,
each corresponding to the passage of a nanoparticle, with the
pulse amplitude yielding the nanoparticle volume, and the
duration corresponding to the particle dwell time and thus
the particle velocity. As the particles are entrained in the
suspending fluid, the pulse duration yields the volumetric flow
rate. One can thus obtain measurements of the concentration
of nanoparticles as a function of nanoparticle size, directly
from the temporal record of electrical resistance. This is a
well-established technique, with the Coulter counter being
the most commonly-used automated instrument for particle
analysis (Vaclavek et al., 2019). At present, there are two
commercially-available RPS instruments for counting and
sizing EVs, the qNano (Izon Science Limited, New Zealand)
and the nCS1TM (Spectradyne LLC, Torrance, CA, USA;
Vaclavek et al., 2019). The qNano instrument expands RPS
technique to a broader range of particle diameters by
using an elastic pore that can be stretched, an approach
known as Tunable Resistive Pulse Sensing (TRPS; Weatherall
and Willmott, 2015). This instrument, however, requires
user-dependent manual settings that reduce data reproducibility
(Tkach et al., 2018). Rather than a single elastic pore, the
MRPSTM technique in the nCS1TM instrument uses disposable
polydimethylsiloxane cartridges, each with a constriction of a
particular size in a microfluidic channel acting as a sensing gate
(Cleland et al., 2016).
In the present study, we used two different disposable
polydimethylsiloxane cartridges, TS-400 and TS-900. TS-400
cartridges were utilized in experiments with S-EVs (range
65–400 nm particle size) and TS-900 cartridges in those with
L-EVs (range 130–900 nm particle size; Cleland et al., 2016;
Grabarek et al., 2019). Samples were first diluted with PBS (1:10)
and then supplemented with 0.1% BSA as recommended by the
instrument manufacturer, and counting and sizing determined
as the average of triplicate measurements on two independent
samples. Since the instrument does not discriminate between
EVs generated by HEI-OC1 cells from those contributed by
the FBS used in cell culture or the abundant silicate particles
present in BSA solutions, the values for the number of particles
per diameter were background-corrected by subtracting bin-
by-bin the numbers obtained in matched control samples of
both culture media containing exosome-depleted FBS (CM+ED-
FBS) and PBS+0.1% BSA. Particle concentration is depicted
in the figures provided by the instrument in the form of
Concentration Spectral Density (CSD), which corresponds to the
density of particles per ml of solution per nm of particle diameter
(particles/ml.nm). The use of CSD allows the comparison of
measurements made with different cartridges since the CSD is
independent of the cartridge parameters and bin widths. The
data, however, can be exported in either CSD or in absolute
concentration (particles/ml), which is obtained by multiplying
FIGURE 1 | Counting and sizing HEI-OC1 extracellular vesicles (HEI-OC1
EVs). (A) Computer-generated concentration spectral density (CSD) vs.
particle size for two independent samples (S1 and S2) in the whole size
range. Values for S1 and S2 are already corrected by bin-by-bin background
subtraction of the values obtained from matched CM+ED-FBS and
PBS+0.1% BSA (see Supplementary Figure S1). Note that the TS-400 and
TS-900 cartridges have an overlapping region. (B) Bar graphic depicting the
total number of particles in the small-EVs (S-EVs) fraction [average of S1 and
S2 = (3.3 ± 0.1) × 109 particles/ml], the total background
[(1.30 ± 0.04) × 108 particles/ml for CM+ED-FBS plus (1.35 ± 0.08) × 108
particles/ml for PBS+0.1% BSA = (2.65 ± 0.12) × 108 particles/ml], and
average of adjusted values [(3.3 ± 0.1) × 109 –
(2.65 ± 0.12) × 108 = (3.0 ± 0.2) × 109 particles/ml]. (C) Bar graphs
depicting the total number of particles in the large-EVs (L-EVs) fraction
[average of S1 and S2 = (1.39 ± 0.07) × 108 particles/ml], the total
background [(4.8 ± 0.2) × 105 particles/ml for CM+ED-FBS plus
(5.3 ± 0.4) × 106 particles/ml for PBS+0.1% BSA = (5.8 ± 0.6) × 106
particles/ml], and average of adjusted values [(1.39 ± 0.69) × 108 –
(5.8 ± 0.6) × 106 = (1.3 ± 0.7) × 108 particles/ml]. Note that in all panels the
scale of the Y-axis is logarithmic, but panel (A) is in CSD units
(particles/ml.nm) whereas panels (B,C) are in absolute concentration units
(particles/ml).
the CSD values by the width of the respective bins. In the present
study, Figure 1A, Supplementary Figure S1 display CSD plots,
but Figures 1B,C as well as numerical values in the text are
provided in absolute concentration.
Proteomic Studies
Bottom-up proteomics was performed using well-established
protocols as recently described (Kalinec et al., 2019). Briefly,
peptide samples were desalted using a modified version of
Rappsilber’s protocol (Rappsilber et al., 2007) and fractionated
via high pH reverse phase chromatography (Agilent Poroshell
120). The fractions were then analyzed by in-line nanobore
reversed-phase chromatography coupled to nanospray
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ionization on a hybrid quadrupole-Orbitrap mass spectrometer
(nLC-MS/MS; QE-Plus, Thermo Fisher Scientific, Waltham,
MA, USA; Capri and Whitelegge, 2017). The data were
processed using Proteome Discoverer 2.2 (Thermo Fisher
Scientific, Waltham, MA, USA), which provides measurements
of relative abundance for the identified peptides, and mined
using mouse protein databases (Kanehisa and Goto, 2000;
Kanehisa et al., 2014).
Loading of EVs and Targeted Lipidomic
Analysis
HEI-OC1 EVs were loaded with 10 mM aspirin (ASP; Catalog
No. A5376, Sigma-Aldrich, St. Louis, MO, USA), arachidonic
(AA), eicosapentaenoic (EPA), docosahexaenoic (DHA), and
linoleic (LA) acids (Sigma-Aldrich, St. Louis, MO, USA), lipoxin
A4 (LXA4) and resolvin D1 (RvD1; CAS No. 89663-86-5 and
CAS No. 872993-05-0, respectively, Cayman Chemical, Ann
Arbor, MI, USA), alone or combined. Loading was performed
by co-incubation for 1 h at 25◦C with sonication for 5 min
(Kalinec et al., 2019), a procedure favored by the hydrophobic
nature of the molecules selected as cargo (Armstrong et al., 2017).
These particular molecules were chosen because they are either
pro-resolving mediators (ASP, LXA4, RvD1) or precursors of
pro-resolving mediators (AA, EPA, DHA, and LA). Unloaded
drug was removed by tangential flow filtration followed by
ultrafiltration and concentration as already described in ‘‘EVs
Isolation and Physical Characterization’’ section. This procedure
increases more than 20-fold the PBS washing volume, rendering
a more thorough wash-out of any unincorporated drug than the
second purification step with exoEasyTM columns performed in
our previous study (Kalinec et al., 2019).
For confirming ASP incorporation by S-EVs
and L-EVs, dried samples were treated with N,O-
bis(trimethylsilyl)trifluoroacetamide reagent (Pierce, 50 µl
of reagent, 60◦C, 60 min), and aliquots (1 µl) of the solution
were analyzed by GC/MS (Thermo Q Exactive GC) for detection
of the trimethylsilyl ASP derivative. Peak areas from the
reconstructed ion chromatograms (m/z 195.04622-195.04818)
for the fragment ion corresponding to the loss of a methyl and
acetyl group from the molecular ion (observed m/z 195.04713,
calculated 195.04720 for C9H11O3Si) were compared to those
obtained from known amounts of ASP treated in the same way.
For targeted lipidomics, S-EVs and L-EVs were divided
into 10 groups: S-Control: S-EVs untreated; S-EVs #2: S-EVs
incubated with 10 mM ASP; S-EVs #3: S-EVs incubated
with 10 mM LXA4 + 10 mM RvD1; S-EVs #4: S-EVs
incubated with 10 mM AA+EPA+DHA+LA; S-EVs #5: S-EVs
incubated with 10 mM AA+EPA+DHA+LA+ASP; L-Control:
L-EVs untreated; L-EVs #2: L-EVs incubated with 10 mM ASP;
L-EVs #3: L-EVs incubated with 10 mM LXA4+RvD1; L-EVs
#4: L-EVs incubated with 10 mM AA+EPA+DHA+LA; L-EVs
#5: L-EVs incubated with 10 mM AA+EPA+DHA+LA+ASP.
Samples of each of these groups were sent to the UC
San Diego Lipidomic Core for fatty acid and eicosanoid
analysis1. As previously described (Eguchi et al., 2016), samples
1http://www.ucsd-lipidmaps.org
were supplemented with 26 deuterated internal standards and
brought to a volume of 1 ml with PBS containing 10%
methanol. They were then partially purified by solid-phase
extraction on Strata-X columns (Phenomenex, Torrance, CA,
USA) following the procedure outlined by the manufacturer.
The columns were eluted with methanol (1 ml), the eluent
was dried under vacuum and redissolved in 50 µl of
buffer A (water/acetonitrile/acetic acid, 60:40:0.02 (v/v/v) and
immediately used for LC-MS analysis. Eicosanoids were analyzed
as previously described (Quehenberger et al., 2010, 2011). Briefly,
eicosanoids were separated by reverse-phase chromatography
using a 1.7-µM 2.1 × 100-mm BEH Shield Column (Waters,
Milford, MA, USA) and an Acquity UPLC system (Waters,
Milford, MA, USA). The column was equilibrated with buffer
A and 5 µl of sample was injected via the autosampler.
Samples were eluted with a step gradient to 100% buffer
B consisting of acetonitrile/isopropanol = 50:50 (v/v). The
liquid chromatography effluent was interfaced with a mass
spectrometer, and mass spectral analysis was performed on
an AB SCIEX 6500 QTrap mass spectrometer equipped with
an IonDrive Turbo V source (AB SCIEX, Framingham, MA,
USA). Eicosanoids and polyunsaturated fatty acids (PUFA)
were measured using multiple reaction monitoring (MRM)
transitions with the instrument operating in the negative
ion mode (Wang et al., 2014). Collisional activation of the
eicosanoid precursor ions was achieved with nitrogen as the
collision gas, and eicosanoids were identified by matching their
MRM signals and chromatographic retention times with those
of pure identical standards. Detailed instrument settings are
summarized elsewhere (Quehenberger et al., 2018). Eicosanoids
were quantified by the stable isotope dilution method. Briefly,
identical amounts of deuterated internal standards were added
to each sample and to all the primary standards used to generate
standard curves. To calculate the amounts of eicosanoids in a
sample, ratios of peak areas between endogenous eicosanoids and
matching deuterated internal eicosanoids were calculated. Ratios
were converted to absolute amounts by linear regression analysis
of standard curves generated under identical conditions.
RESULTS
Counting and Sizing EVs
Previous studies of our laboratory showed that auditory
HEI-OC1 cells generate abundant EVs (Kalinec et al., 2019).
This earlier study, however, suggested that they were mostly
L-EVs, with a significant lower number of S-EVs. This was an
unexpected result that, if confirmed, would indicate that the
mechanism of EV generation could be different in HEI-OC1 than
in other cell populations. Thus, the first goal of the present study
was to evaluate the number of S-EVs and L-EVs generated by
HEI-OC1 cells. Since the nanotracking technique used in our
previous study is dependent on the optical properties of the
particles, which vary with their size, we switched to a different
technique, Microfluidic Resistive Pulse Sensing (MRPS).
The data provided by the nCS1TM MRPS instrument, using
TS-400 and TS-900 cartridges, is summarized in Figure 1. The
number of particles vs. diameter of particle curves corresponding
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to S-EVs and L-EVs from two independent samples (#1 and
#2) are depicted in Figure 1A, with values expressed in CSD
units (particles/ml.nm). Each point of these curves represents
the average of three measurements per sample, and they are
already adjusted by bin-by-bin background subtraction of the
values obtained from matched CM+ED-FBS and PBS+0.1%
BSA control samples (confidence intervals are depicted by the
diameter of the graphic points corresponding to every value;
for background values, also in CSD units, see Supplementary
Figure S1). The data shows that the number of EVs varies in
inverse proportion to their size, with a maximum of around
1 × 107 particles/ml and a minimum of about 1 × 105
particles/ml for S-EVs, and a range of around 1 × 106 to
1 × 103 particles/ml for L-EVs (note that these values are
expressed in absolute concentration units). When the areas
under the size distribution plots were summed, and background
subtracted, the S-EVs samples contained an adjusted average
of (3.0 ± 0.2) × 109 particles/ml, corresponding to a total of
(3.3 ± 0.1) × 109 particles/ml minus (2.65 ± 0.08) × 108
particles/ml for background (Figure 1B). L-EVs samples, in turn,
contained an adjusted average of (1.3 ± 0.7) × 108 particles/ml,
as a consequence of a total value of (1.39 ± 0.69) × 108
particles/ml in experimental samples and (5.8 ± 0.4) × 106
particles/ml for background (Figure 1C). Thus, in contrast to
the results using the nanotracking technique (Kalinec et al.,
2019), our present data indicate that HEI-OC1 cells generate
more S-EVs than L-EVs. Other information apparent from
these figures is that the fractions are not absolutely ‘‘pure,’’
since the S-EVs one still contains a certain number of particles
with diameters larger than 150 nm and, vice-versa, the L-EVs
fraction contains vesicles with diameters smaller than 150 nm
(Figure 1A).
Interestingly, using the formulas V = 4/3 (pir3) and S = 4
pir2, the particle diameters provided by the nCS1TM instrument
to estimate the EVs’ radius, and assuming the EVs are perfectly
spherical, the calculated total volumes (S-EVs = 3.1 × 1014
nm3; L-EVs = 6.4 × 1014 nm3) and surface (membrane) areas
(S-EVs = 1.8× 1013 nm2; L-EVs = 1.2× 1013 nm2) of the vesicles
present in each fraction are of the same order of magnitude.
Protein Profiling of HEI-OC1 EVs
Next, we wonder whether S-EVs and L-EVs shared a similar
protein profile or, instead, they contain some unique protein
markers that could be used for identification or classification. To
investigate this issue, we performed bottom-up proteomics.
A total of 620 bona fide EV proteins were detected in
our proteomic studies, 489 of them in the S-EVs fraction
and 131 in the L-EVs fraction (Supplementary Tables S1,
S2). From them, 381 (61.5%) were unique for S-EVs, 23
(3.7%) were specific for the L-EVs, and 108 (17.4%) were
found in both fractions. Interestingly, 86.7% (26 out of 30)
of the proteins listed in the ExoCarta exosome database as
those more frequently identified in exosomes (Keerthikumar
et al., 2016) were detected in S-EVs; in contrast, only
15 out of these 30 (50%) were detected in the L-EVs
fraction. CD63, CD81, and PDCD6IP (aka Alix), all considered
exosome biomarkers, were identified only in S-EVs (Table 1).
TABLE 1 | Expression in small extracellular vesicles (S-EVs) and large EVs
(L-EVs) fractions of the proteins more frequently identified in exosomes.
Score ExoCarta Gene symbol Present in S-EVs? Present in L-EVs?
1 CD9 - -
2 HSPA8 YES YES
3 PDCD6IP YES -
4 GAPDH YES YES
5 ACTB YES YES
6 ANXA2 YES -
7 CD63 YES -
8 SDCBP - -
9 ENO1 YES YES
10 HSP90AA1 YES YES
11 TSG101 - -
12 PKM YES YES
13 LDHA YES -
14 EEF1A1 YES YES
15 YWHAZ YES YES
16 PGK1 YES YES
17 EEF2 YES YES
18 ALDOA YES -
19 HSP90AB1 YES YES
20 ANXA5 YES -
21 FASN - -
22 YWHAE YES YES
23 CLTC YES -
24 CD81 YES -
25 ALB YES YES
26 VCP YES YES
27 TPI1 YES -
28 PPIA YES -
29 MSN YES -
30 CFL1 YES YES
ExoCarta: http://exocarta.org/Archive/ExoCarta_top100_protein_details_5.txt. Accessed
January 29, 2019. Twenty-six out of the 30 (86.7%) proteins more frequently identified in
exosomes were found in S-EVs, but only 15 (50%) of them were found in L-EVs.
More importantly, the protein mediators of inflammatory
resolution Annexin A1 (ANXA1) and Galectins 1 and 3 (Gal-
1 and Gal-3) were only detected in the S-EVs fraction too
(Supplementary Tables S1, S2). On the other hand, only one
cytokine (CSF1, colony-stimulating factor 1) was detected in
HEI-OC1 EVs, but it was present in both fractions S-EVs
and L-EVs.
Except for the difference in the total number of proteins
in each fraction, the distribution profiles by cellular origin,
biological and molecular functions were quite similar in S-
EVs and L-EVs (Figures 2–4). Most of the proteins detected
in both fractions originated from cell membranes, cytoplasm,
nucleus, or cytosol, with minor percentages of extracellular
origin or from organoids (mitochondria, endoplasmic reticulum)
and the cytoskeleton (Figure 2). They were mostly involved in
metabolism or regulation of other biological processes, as well
as in response to stimuli, cell organization and biogenesis, and
transport (Figure 3). The most common function was molecular
binding, either to other proteins, RNA, metal ions or nucleotides,
but proteins with catalytic or structural function were also
significantly represented (Figure 4). In every case, the proteins
identified as ‘‘Others’’ include all those belonging to groups with
less than 5% of the total.
In summary, we found that the S-EVs fraction contains
a larger number and greater diversity of proteins than the
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FIGURE 2 | Proteomic analysis. Characterization of proteins from HEI-OC1 EVs by cellular localization.
L-EVs, but the similarities observed in their distribution profiles
(Figures 2–4) suggest that this difference could be associated
with the involvement of a more efficient cellular mechanism of
protein sorting and/or loading into S-EVs from a single pool of
molecules rather than the existence of two different pools, one
for S-EVs and other for L-EVs. The presence of ANXA1, Gal-1,
and Gal-3 makes S-EVs more attractive as potential nanocarriers
in pro-resolving therapies.
EVs’ Loading and Target Lipidomic
Analysis
The absence of toxic effects and the ability to incorporate
as cargo the drugs and molecules of interest are crucial
requirements for a useful drug carrier. As already mentioned,
EVs are not toxic, lack endogenous tumor-formation potential,
and they show very low immunogenicity. In addition, they
can be easily loaded with pharmacological agents using simple
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procedures. Therefore, we decided to investigate the loading
of S-EVs and L-EVs from HEI-OC1 cells with ASP, the
eicosanoids LXA4, RvD1, and the PUFA AA, DHA, EPA, and
LA, all of them recognized anti-inflammatory and pro-resolving
agents. While ASP incorporation was evaluated by GC/MS,
eicosanoids were identified and quantified by targeted lipidomics
using LC/MS/MS-MRM. Importantly, in addition to revealing
the identity and concentration of around 150 eicosanoids,
PUFA, and related compounds, the lipidomic profiles revealed
the presence and amounts of endogenous pro-inflammatory
components that could counter the pro-resolving effects of
the cargo.
Co-incubation of HEI-OC1 EVs (10 ml, with 1 × 108
S-EVs and L-EVs per ml) with ASP (10 mM) resulted in the
incorporation of 6.9 ± 0.1 µg/ml (∼38 µM) of ASP in S-EVs
samples, and 61.8 ± 0.6 µg/ml (∼0.34 mM) ASP in L-EVs
samples. These results suggest that EVs, particularly L-EVs
could be loaded with pharmacologically effective quantities of
this drug.
Of the 150 components of the lipidomic profiles, only 19 were
detected in untreated (Control) samples, with four of them
detected only in S-Control, six only in L-Control, and nine
found in both fractions (Figure 5, Supplementary Table S3). In
addition, while free AA, DHA, and EPA were found in untreated
EVs, LXA4, ATL-LXA4, Resolvins, Maresins, and Protectins
were not detected (Table 2, Supplementary Table S3).
As shown in Table 2 both, S-EVs #3 and #4 and L-EVs
#3 and #4, were able to simultaneously incorporate AA,
EPA, and DHA in amounts between 5 and 6 nmol per ml
of suspension (about 1.5–2.0 ng/ml). Importantly, in EVs
loaded with these PUFA, all 19 metabolites originally detected
in S-Control and L-Control samples (Figure 5) showed
an increased concentration in both fractions. Moreover,
50 other metabolites previously undetected were found in
these EVs, making a total of 69 eicosanoids identified in the
samples (Supplementary Table S3). Inflammatory agents
were not detected in Control and ASP-loaded EVs, but
those loaded with PUFAs generate several prostaglandins
[e.g., PGD2(189.18 pmol/ml], PGE2(48.94 pmol/ml), PGF2a
(15.64 pmol/ml), leukotriene B4 (LTB4, 3.84 pmol/ml),
and thromboxane B2 (TXB2, 1.18 pmol/ml), among others
(Supplementary Table S3). The generation of PUFA derivatives
suggests the existence of an active biosynthetic mechanism
within HEI-OC1 EVs. LXA4 and AT-LXA4 (ASP triggered-
LXA4) were also detected in these groups in amounts varying
roughly between 3 and 10 pmol/ml (about 0.35 ng/ml). Since
the limit of detection of the lipidomic experiments was around
0.002 pmol/ml, the measured values represent increases of at
least 3–4 orders of magnitude (1,000-fold to 10,000-fold) relative
to the control conditions. As expected, S-EVs and L-EVs also
incorporated LXA4 and RvD1, although in lower amounts
than their precursors AA, EPA, and DHA. It should be noted,
however, that the amounts of LXA4 and RvD1 incorporated
by HEI-OC1 EVs ranged from 15 to 210 pmol/ml (roughly
5–70 µg/ml), six orders of magnitude higher than the normal
concentrations of these pro-resolving mediators in human serum
[2–120 pg/ml (Colas et al., 2014; Dalli et al., 2017)]. Curiously,
AT-LXA4 was not found in ASP-loaded EVs (S-EVs #2 and #5,
and L-EVs #2, and #5), but was detected in EVs loaded with
LXA4 (S-EVs #3 and L-EVs#3) and AA, its fatty acid precursor
(S-EVs #4 and #5, and L-EVs #4, and #5).
DISCUSSION
The present study provides evidence that auditory HEI-OC1
cells generate abundant EVs, both small (<150 nm diameter)
and larger (>150 nm diameter), which can be loaded with
anti-inflammatory drugs, PUFA, and pro-resolving mediators,
either alone or combined, in amounts significantly higher
than those normally found in human serum. Proteomic
studies detected a differential presence of selected proteins in
S-EVs and L-EVs fractions. In particular, S-EVs contained
a larger variety of proteins, including the pro-resolving
mediators ANXA1, Gal-1 and Gal-3, than L-EVs. Targeted
lipidomic studies, in turn, identified eicosanoids that were
present in one of the EV fractions and not in the other.
These results support the idea that HEI-OC1 EVs could
be advantageously used as nanocarriers for delivery of
drugs and molecular mediators aimed at facilitating the
resolution of inflammatory processes. In particular, they could
potentially be useful as vehicles for the intracochlear delivery of
pro-resolving agents aimed at preventing or alleviating DRHL
and NRHL.
Counting and Sizing EVs
The present results indicate that HEI-OC1 cells secrete near
two orders of magnitude more S-EVs than L-EVs, with the
number of EVs decreasing monotonically with their increase
in diameter (Figure 1A). Since the instrument used for the
measurements counts individual particles and estimates their
diameter, arithmetic calculations from the data (assuming that
all the EVs were perfect spheres) indicated that the total
volume and total membrane area of the vesicles present in
each fraction were of the same order of magnitude, suggesting
that the drug-loading capability of both fractions should be
roughly similar.
The abundance of S-EVs is in contradiction to the data
we reported in a recent publication, where the counting and
sizing of HEI-OC1 EVs were based on light-scattering technology
(Kalinec et al., 2019). The distribution of EVs by size as estimated
with that technique showed a low concentration of particles
with diameters below 200 nm, suggesting that HEI-OC1 EVs
consisted mostly of L-EVs. However, as already discussed in
that publication, although currently considered as reliable, light-
scattering techniques are not exempt from problems (Witwer
et al., 2013; Koritzinsky et al., 2017; Grabarek et al., 2019).
In particular, particles with an optical index close to that of
the suspension medium or with high curvature radius (small
diameter) scatter much less light than those with a significantly
different index or larger diameter. This sensitivity dependence
makes small biological particles essentially undetectable (Cleland
et al., 2016; Grabarek et al., 2019), a fact that could explain
the difference between our preliminary results and those
reported here.
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FIGURE 3 | Proteomic analysis. Characterization of proteins from HEI-OC1 EVs by associated biological process.
In the present study, HEI-OC1 EVs were counted and
sized with an instrument (Spectradyne nCS1TM) based on a
completely different technique, Microfluidic Resistive Pulse
Sensing (MRPSTM; Cleland et al., 2016; Grabarek et al., 2019).
MRPS is based on monitoring transient changes in electric
current, also known as the Coulter principle, caused by
particles passing through a narrow orifice (Song et al., 2017).
Using the nCS1TM for counting and sizing, EVs have some
important advantages. The nCS1TM is capable of measuring
the size distribution of EVs with diameters ranging from
35 nm up to 10 µm over concentrations ranging from 107 to
1012 particles/ml, and statistically significant data sets can be
acquired rapidly (minutes). Because the nCS1TM uses electrical
sensing, not optical detection, measurements are independent
of the material properties of the particles. Importantly, the
small sample volume required for analysis (3 µl) is set by
the size of the analyte reservoir in the disposable cartridge.
Moreover, the measurement does not rely on user-adjustable
parameters, rendering more reproducible results. Although
not completely free of limitations (analysis of particles with
diameters <55 nm with this technique is still complicated,
and the use of different cartridges makes cumbersome
the evaluation of samples with a big range of particle’s
diameters), MRPS is probably the best currently available
technique for analyzing particles in the nanometer range
(Grabarek et al., 2019).
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FIGURE 4 | Proteomic analysis. Characterization of proteins from HEI-OC1 EVs by molecular function.
Protein Profiles of S-EVs and L-EVs
A recent ‘‘consensus’’ publication, co-authored by several
prominent scientists in the field of EVs, stated that ‘‘EVs in the
small size range likely represent vesicles heterogeneous in origin’’
with unknown portions of exosomes and ectosomes (Mateescu
et al., 2017). The definition of larger EVs is even less precise, with
these vesicles comprising a wide range of membrane-enclosed
entities. Indeed, it is not yet clear how to divide EVs into
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FIGURE 5 | Lipidomic analysis. Only 19 out of 150 metabolites investigated were detected in Control HEI-OC1 EVs, four of them in S-EVs, six in L-EVs, and nine in
both fractions. Values expressed in pmol/ml. ND, Not Detected.
TABLE 2 | Lipidomic analysis.
Group Free AA Free EPA Free DHA AT-LXA4 LXA4 RvD1
S-Control 17.84 0.52 6.02 ND ND ND
S-EVs #2 28.86 0.72 10.34 ND ND ND
S-EVs #3 50.02 2.20 19.62 1.56 55.40 15.44
S-EVs #4 6,370.88 4,764.42 5,149.18 20.26 24.46 ND
S-EVs #5 5,872.28 4,633.08 5,625.40 13.36 15.94 ND
L-Control 154.54 94.24 110.38 ND ND ND
L-EVs #2 73.98 38.58 47.52 ND ND ND
L-EVs #3 25.28 12.64 13.92 6.26 207.34 70.70
L-EVs #4 3,596.42 2,707.80 3,438.06 8.00 9.14 ND
L-EVs #5 2,183.12 2,387.16 2,393.28 7.36 9.24 ND
Incorporation of fatty acids and pro-resolving mediators by HEI-OC1 EVs. S-Control: S-EVs untreated; S-EVs #2: S-EVs incubated with 10 mM ASP; S-EVs #3: S-EVs incubated
with 10 mM LXA4 + 10 mM RvD1; S-EVs #4: S-EVs incubated with 10 mM AA+EPA+DHA+LA; S-EVs #5: S-EVs incubated with 10 mM AA+EPA+DHA+LA+ASP; L-Control: L-EVs
untreated; L-EVs #2: L-EVs incubated with 10 mM ASP; L-EVs #3: L-EVs incubated with 10 mM LXA4+RvD1; L-EVs #4: L-EVs incubated with 10 mM AA+EPA+DHA+LA; L-EVs #5:
L-EVs incubated with 10 mM AA+EPA+DHA+LA+ASP. Results are expressed in pmol/ml. ND, Not Detected.
their relevant subtypes, or even how many functionally distinct
subtypes are there (Mateescu et al., 2017). In addition, every
EV subtype could have different protein and lipid composition
and, consequently, a different function (Kowal et al., 2016;
Willms et al., 2016). Thus, recent studies have searched for a
better characterization of different EV subtypes, and one of the
common classifications is division by size into small and large
(Vagner et al., 2019). A similar approach was followed in the
present study.
Our results show that S-EVs and L-EVs do not contain the
same repertoire of proteins. In fact, only 17.4% (108 out of
the 620) proteins identified as belonging to HEI-OC1 EVs are
common to both fractions, whereas 61.5% (381 out of 620)
are unique to S-EVs and 3.7% (23 out of 620) were found
only in L-EVs. As shown in Table 1, 86.7% of the proteins
more frequently found in exosomes were present in S-EVs from
HEI-OC1 cells, whereas only 50% were also present in the L-EVs
fraction. Two proteins (SDCBP, an adapter protein involved in
exosome biogenesis, and FASN, a fatty acid synthase) frequently
identified in exosomes and previously reported in HEI-OC1 EVs
(Kalinec et al., 2019) were not detected in the present study.
Interestingly, the protein most frequently found in exosomes
from other cell populations, tetraspanin CD9, was also absent in
EVs from HEI-OC1 cells. This confirmed our preliminary results
(Kalinec et al., 2019), and those of others, suggesting that not all
S-EVs have the same tetraspanin profile (Vagner et al., 2019).
For instance, CD9 and CD63 were variably detected in S-EVs
and L-EVs, whereas CD81 was exclusively detected in S-EVs.
However, only the co-localization of CD81 with CD63 qualifies
an S-EV as an exosome (Kowal et al., 2016; Tkach et al., 2018).
Thus, we can conclude that our S-EVs samples probably contain
classical exosomes since CD63 and CD81 were abundant in this
fraction (Table 1).
Other difference between our current and earlier preliminary
results was the finding of ANXA1 and ANXA5 in S-EVs
(Supplementary Tables S1, S2). We commented in our previous
work the oddity that ‘‘two of the most common annexins
found in exosomes (ANXA1 and ANXA5) were either found
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at low levels or not appeared at all’’ in our samples (Kalinec
et al., 2019). The fact that both of them were now found
only in the S-EVs fraction suggests that they were probably
present in our preliminary samples, but in non-detectable levels.
The presence of ANXA1, in particular, provides important
support to our idea of using HEI-OC1 EVs as nanocarriers
of drugs and molecular mediators aimed at the resolution of
inflammatory responses in the cochlea. ANXA1 (Annexin A1)
is a potent anti-inflammatory and pro-resolving protein (see
Kalinec et al., 2017 and references therein). Many of the cellular
and molecular processes associated with the anti-inflammatory
properties of glucocorticoids are modulated by ANXA1, and it
is considered an important modulator of both the innate and
adaptive immune systems.
Interestingly, the authors of a recent publication (Jeppesen
et al., 2019) proposed that ANXA1 would be a specific marker
of microvesicles shed from the plasma membrane, and ANXA5 a
component of apoptotic vesicles. The subcellular distribution of
ANXA1 is unusual (for instance see Buckingham and Flower,
2017); it is abundant in the cytoplasm of some cell populations,
but a small proportion is also found on the external surface
of the plasma membrane or attached to their inner leaflet.
Sometimes, even a single membrane pool of ANXA1 has been
detected in particular cells. In guinea pig Hensen cells (Kalinec
et al., 2009) and HEI-OC1 cells, ANXA1 was found in the
cytoplasm, with membrane localization observed only after
stimulation with glucocorticoids; in contrast, Jeppesen et al.
(2019) localized ANXA1 only in the plasma membrane of
DKO-1 and Gli36 human cancer cells, which they used in the
reported study. Therefore, while Jeppesen et al. (2019) detected
only membrane-bound ANXA1 in microvesicles from human
cancer cells, cytoplasmic ANXA1 could be abundant in exosomes
from auditory HEI-OC1 cells. Likewise, although ANXA5 is
prominent in apoptotic vesicles, its presence in exosomes or
microvesicles from some cell populations cannot be discarded.
We also confirmed the presence in S-EVs of Gal-1 and Gal-3
(Supplementary Tables S1, S2), a family of glycan-binding
proteins that regulate the initiation, amplification and resolution
of acute and chronic inflammatory responses (see Kalinec et al.,
2017 and references therein). Gal-1 has been associated with a
range of anti-inflammatory effects on various cell types, whereas
Gal-3 enhances the phagocytic capabilities of neutrophils, a
property that may in part account for its protective role in
infections. On the other hand, the only pro-inflammatory
cytokine detected in HEI-OC1 EVs, the Colony Stimulating
Factor 1 (CSF-1), was found in both fractions. CSF-1 is known
to be involved in the proliferation, differentiation, and survival
of monocytes and macrophages, and it has been implicated in
promoting tissue repair following injury (Zhang et al., 2012).
Recently, however, it was proposed that CSF-1 has a dual
role as pro-inflammatory and anti-inflammatory/regulatory
cytokine dependent on the particular immune response
(Bhattacharya et al., 2015).
Lipids in S-EVs and L-EVs
Lipids are involved in a number of crucial cellular functions.
For instance, in addition to be essential components of
cellular membranes, lipid mediators play important roles in
cell signaling, including inflammation and immunity (Poorani
et al., 2016). It is well known that specific lipids are enriched in
EVs compared to their parent cells (Skotland et al., 2017), and
there are several possible explanations for these dissimilarities.
The composition of the cell medium is important for the
lipid composition of the cells and most probably for EVs lipid
profile too (Stoll and Spector, 1984). Different growth conditions
may also contribute, since different cell densities may change
the lipid composition of a cell and intracellular trafficking
pathways (Kavaliauskiene et al., 2014). However, since in our
experiments all these factors were identical for S-EVs and L-EVs,
any difference should be associated with the precise origin of
the particles.
LXA4, AT-LXA4, Resolvins, Maresins, and Protectins, in
contrast to free AA, DHA, and EPA, were not detected in
S-Control and L-Control (Table 2, Supplementary Table S3).
On the other hand, four eicosanoids unique to S-EVs and
six unique to L-EVs were detected in Control samples, while
another nine were common to both fractions (Figure 5). Those
unique to S-Control were the HydroxyEicosaTetraEnoic acids
8-HETE, 15-HETE, and 8-HETrE, which derive from AA, and
16-HDoHE (HydroxyDocosaHexaEnoic acid), an autoxidation
product of DHA (Poorani et al., 2016; for a complete list
of eicosanoid abbreviations see Supplementary Table S3,
worksheet 3). These products of PUFAs are pre-dominantly pro-
inflammatory, but they are also intermediaries in the generation
of lipoxins and epi-lipoxins and enhance the generation of
nitric oxide (NO), another pro-resolving mediator (Kalinec
et al., 2017). Interestingly, two pro-inflammatory eicosanoids,
prostaglandin D2 (PGD2) and 13,14-dihydro-15-keto-PGE2
(DHK-PGE2), were detected in L-Control but not in S-Control
(Figure 5). In mammals, large amounts of PGD2 are found
only in mast cells and the brain; in fact, PGD2 is the most
abundant prostaglandin in the brain and the one that changes
the most under pathological conditions (Figueiredo-Pereira
et al., 2015). While prostaglandin E2 (PGE2) and 15-deoxy-
∆12,14-prostaglandin J2 (15-d-PGJ2) are frequently found in
EVs (Subra et al., 2010), to our knowledge the literature
only reports the presence of PGD2 in EVs in one study
performed on exosomes from RBL-2H3 cells, a mast cell
model (Subra et al., 2010). Other eicosanoids only detected
in L-Control were 15-oxoETE (oxo EicosaTetraEnoic acid, an
oxylipin produced by oxidation of 15-HETE), 14(15)-EpETE
[a cytochrome P450 (CYP)-metabolite of EPA], 9(10)-EpOME
and 12(13)-EpOME (products of the metabolism of linoleic
acid by CYP enzymes). Just like all those detected in both
fractions, these metabolites participate in pro-inflammatory and
pro-resolving pathways, suggesting they are part of a delicate
physiological balance.
An important piece of information provided by our lipidomic
studies was the significant increase in the variety and amount
of lipid metabolites present in EVs loaded with AA, EPA, and
DHA (see below). More than 50 metabolites undetected in
S-Control or L-Control were found in these EVs, making a total
of 69 eicosanoids identified in our samples (Supplementary
Table S3). For instance, in the absence of exogenously added
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PUFAs few pro-inflammatory eicosanoids were detected, and
those that were detected were present at trace levels. In contrast,
prostaglandins PGD2, DHK-PGE2, PGF2α, PGE2, PGE1, PGD1,
PGE3, PGD3, 15K PGF2α, 15K PGE2, DHK-PGD2, 11β PGE2,
Thromboxane B2 (TXB2), and other pro-inflammatory agents
were detected in both S-EVs and L-EVs loaded with PUFAs
(Supplementary Table S3). The data suggest that all pathways,
including those mediated by COX (cyclooxygenase), 5-LOX
(lipooxygenase), 12-15 LOX and CYP (cytochrome P450), are
endogenously present in the HEI-OC1 EVs, and are sufficiently
active to produce abundant molecular products when supplied
with substrates. It should be emphasized that, since EVs were
loaded exogenously in the absence of cells, we can confidently
assume that all these molecular products were generated
in the EVs, suggesting the existence in EVs of an active
metabolic mechanism.
Most of these AA, EPA and DHA metabolites are part
of pathways that give rise not only to potent pro-resolving
mediators but also to pro-inflammation agents. Many of
the prostaglandins, including the highly induced PGD2, are
considered pro-inflammatory. In general, under steady-state
physiological conditions, one would expect a balance between
pro- and anti-inflammatory molecules so that homeostasis is
preserved. When this balance is altered, depending on the side to
which it is tilted, either there will be suppression or exaggeration
of inflammation. Our results suggest that incorporation of
PUFAs as cargo induces the generation of pro-inflammatory
agents in the HEI-OC1 EVs, which could interfere with the goal
of accelerating the resolution of inflammatory processes. Thus,
if HEI-OC1 EVs are used as nanocarriers, their cargo should be
carefully tailored to ensure that it will promote the return to the
normal balance.
Loading of S-EVs and L-EVs
EVs are able to incorporate as cargo different types of molecules,
such as miRNAs, messenger RNAs, siRNAs, proteins, and
even drugs like doxorubicin and curcumin (Sun et al., 2010;
Lai et al., 2013; Yang et al., 2015). Moreover, EVs can be
loaded exogenously or endogenously. In the first approach, the
molecule of interest is included in EVs after isolation, while
the endogenous approach is based on active encapsulation,
particularly during EV biogenesis, via transforming the
producing cells with the selected molecule (Pinheiro et al.,
2018). EVs loading, however, depends on different factors,
including the cellular origin of the EVs, which dictates their
molecular composition, and the physical-chemical properties
of the intended cargo (e.g., hydrophobicity). In the case
of hydrophilic drugs, for instance, special strategies such
as hydrophobic insertion, covalent surface chemistry, and
membrane permeabilization, may be necessary to facilitate
loading (Armstrong et al., 2017). Incorporation of drugs like
dexamethasone and aspirin inside EVs, on the other hand,
should not be a surprise, since they are hydrophobic. Likewise,
fatty acids and lipid mediators should be easily incorporated.
However, the loading of other drugs and molecules of interest
by HEI-OC1 EVs must be demonstrated before serious
consideration of their use as nanocarriers.
Incorporation of dexamethasone by HEI-OC1 EVs was
already reported in our preliminary study (Kalinec et al.,
2019), and here we present proof that they can be loaded
with ASP, LXA4, RvD1, and the eicosanoid precursors AA,
EPA, and DHA. These results support the idea that HEI-OC1
EVs could be ideal vehicles for intracochlear delivery of drugs
and molecular mediators aimed at facilitating the resolution of
cochlear inflammatory processes.
The amount of ASP incorporated by HEI-OC1 EVs was
surprisingly high, with significantly more loading by L-EVs
(61.8 ± 0.6 µg/ml) than by S-EVs (6.9 ± 0.1 µg/ml). Since
the volume of L-EVs per ml is only about twice the volume
of S-EVs per ml (6.4 × 1014 nm3 vs. 3.1 × 1014 nm3), we
speculate that could be some structural problem limiting ASP
incorporation in S-EVs. For instance, the different loading of
ASP by S-EVs and L-EVS could be related to differences in the
curvature of the EV membrane and/or surface charge (Zhou
and Raphael, 2007). It has been shown that ASP interacts
with membrane lipids, being incorporated first to the external
layer and translocating to the internal by flip-flop before being
internalized. During this process, the physical properties of the
full structure, including their thickness, bending elasticity, and
permeability, are affected (Zhou and Raphael, 2005; Sharma
et al., 2017). These changes could be more significant in small
EVs, hindering the incorporation of ASP, while L-EVs could
more readily accommodate the salicylate molecules (Zhou and
Raphael, 2007).
ASP, in addition to its proven anti-inflammatory, pro-
resolving, and anti-oxidant properties, is the only drug to
date that has shown beneficial effects for the mitigation of
sensorineural hearing loss in clinical trials (see Kalinec et al., 2017
and references therein). ASP not only blocks the biosynthesis of
prostaglandins but also stimulates the endogenous production
of pro-resolving mediators, such as ASP-triggered lipoxins (AT-
LXs) and resolvins (AT-RVs), which promote the resolution
of inflammation by stimulating phagocytosis of cellular debris
and counter-regulate pro-inflammatory cytokines without being
immunosuppressive (Serhan, 2014). ASP-triggered pro-resolving
mediators are generated by the activity of ASP-acetylated
cyclooxygenase on PUFA substrates, including AA, EPA, and
DHA (Clària and Serhan, 1995; Clària et al., 1996; Serhan
et al., 2002; Dalli et al., 2013; Serhan, 2014). In addition
to exhibiting similar anti-inflammatory and pro-resolving
characteristics of native mediators, the ASP-triggered forms
(R epimers) resist rapid inactivation by oxido-reductases and
have longer in vivo half-lives (Serhan, 2014). Intriguingly,
our present results indicate that incorporation of ASP as
cargo did not produce detectable amounts of AT-LXA4 in
HEI-OC1 EVs in contrast to the significant amounts found
in EVs loaded with AA, EPA and DHA (Table 2: compare
groups S-EVs #2 and L-EVs #2 with S-EVs #4 and #5, and
L-EVs #4 and #5). These results present a puzzle: how is
an ASP-triggered mediator produced in the absence of ASP,
and why the generation of an ASP-triggered mediator is
not affected by the presence of ASP? Since ASP-acetylated
COX-2 generates ATLs from PUFA, we can speculate that
minimum amounts of acetylated COX-2 could be naturally
Frontiers in Cellular Neuroscience | www.frontiersin.org 13 November 2019 | Volume 13 | Article 530
Kalinec et al. HEI-OC1 EVs as Drug Nanocarriers
present in EVs and the process triggered by an excess of
substrate even in absence of ASP. Conversely, if no PUFAs
are present, even incorporation of abundant ASP will not
trigger the production of ATLs because of the absence
of substrate. However, without specific data, this is only
guesswork and, clearly, finding answers to these questions
require further investigation.
Whereas the incorporation of lipid precursors and
pro-resolving mediators by HEI-OC1 EVs was not unexpected
given their hydrophobic nature, the amounts were surprisingly
high. All these agents were found in concentrations roughly six
to seven orders of magnitude higher than the normal values
present in human serum [micrograms/ml in HEI-OC1 EVs
vs. picograms/ml in human serum (Colas et al., 2014; Dalli
et al., 2017)]. Therefore, delivery of very small volumes of EV
suspension would be sufficient to reach clinically significant
amounts of these pro-resolving mediators in specific organs and
tissues. This is particularly important for their intracochlear
delivery, given the small size of the auditory organ.
Other very important result is the demonstration that
EVs can be loaded simultaneously with different precursors
and drugs and that this can be accomplished by simple
co-incubation of the EVs with the different agents. As abundantly
described in the literature, EVs have been loaded with different
molecules either endogenously or exogenously. For instance,
mesenchymal and tumor cells incubated with chemotherapeutic
drugs, subsequently produced EVs loaded with these drugs (Tang
et al., 2012; Pascucci et al., 2014). The main disadvantage of this
endogenous approach, however, is that drug incorporation into
the cells and into the EVs depends on the particular cells and
the mechanisms involved in molecular sorting into EVs, which
largely remain to be elucidated. The exogenous approach, which
involves loading of EVs after their isolation as described here, is
simpler, but not exempt of potential complications. For example,
incorporation of hydrophilic agents may be problematic, but
even in these situations high loading efficiencies can be obtained
with sonication, extrusion or following saponin treatments
(Vader et al., 2016).
S-EVs or L-EVs?
As known from the literature (Mathivanan et al., 2010; Bobrie
et al., 2012; Romancino et al., 2013; Zaborowski et al., 2015;
Kowal et al., 2016; Xu et al., 2016; Vagner et al., 2019) and
confirmed by our results, S-EVs and L-EVs have different
composition and, probably, different functions. Since we are
interested in using them as nanocarriers of pre-defined molecular
cargoes to play specific functions, we wonder whether one of
these fractions could be more qualified than the other to be
exploited for our therapeutic goal.
One important parameter, the potential amount of cargo
able to be incorporated by one fraction or the other, provided
some interesting hints. As reported in ‘‘Results’’ section, the total
volume and surface (membrane) area of the vesicles present in
each fraction are of the same order of magnitude, suggesting
that they should be able to incorporate nearly similar amounts
of exogenous cargo. However, the already discussed issue of ASP
incorporation indicates that this is not necessarily true.
Proteomic results suggest that HEI-OC1 S-EVs, but not
L-EVs, contain ANXA1, Gal-1 and Gal-3, known regulators and
mediators of inflammation resolution (Kalinec et al., 2017). This
result makes S-EVs more attractive as potential nanocarriers in
pro-resolving therapies. In addition, they contain many unique
proteins that are probably part of the proteome of the parent
cells and could perhaps be associated with the function and/or
protection of the hearing organ (Kowal et al., 2016; Kalinec
et al., 2019). However, dexamethasone can be incorporated as
cargo in any EV, and it is already known that this glucocorticoid
induces the release of ANXA1 (Kalinec et al., 2009), galectins and
other proteins from Hensen cells of the organ of Corti (Kalinec
et al., unpublished). Thus, the differences in the proteome of
S-EVs and L-EVs could be compensated, at least partially, by
the judicious choice of their cargo to include the right molecules
and/or pharmacological agents.
Our lipidomic studies showed only small differences between
S-Control and L-Control. Most importantly, they showed a huge
increase in the variety and amount of lipid metabolites present in
EVs of both fractions loaded with AA, EPA, and DHA, erasing
any potential difference between S-Control and L-Control
(Supplementary Table S3). Although the idea of loading
EVs with precursors of pro-resolving mediators, expecting
their transformation into lipoxins, resolvins, protectins
and/or maresins in the target organ, was very attractive,
the observed generation of a number of pro-inflammatory
agents inside the EVs makes it inconvenient. In contrast,
the fact that L-EVs showed a more efficient incorporation
of ASP, LXA4, and RvD1 than S-EVs suggests that larger
vesicles could be more effective carriers for anti-inflammatory
and pro-resolving agents than smaller ones. Nevertheless,
experiments aimed specifically at comparing S-EVs and
L-EVs drug delivery to particular organ or cell targets must
be performed before arriving at a definitive conclusion.
Studies pursuing this goal are currently being performed in
our laboratory.
CONCLUSION
In the present study, we provide evidence that auditory
HEI-OC1 cells generate abundant EVs that can be loaded with
combinations of anti-inflammatory drugs and pro-resolving
agents in significantly higher concentrations than those normally
required for clinical significance. Proteomic and lipidomic
studies detected a differential distribution of selected proteins
and lipids between small (S-EVs) and large (L-EVS) vesicles.
For instance, the S-EVs fraction contains a larger number and
diversity of proteins than the L-EVs that could be associated
with the involvement of a more efficient cellular mechanism
of protein sorting and/or loading. In particular, S-EVs contain
the pro-resolving protein mediators ANXA1, Gal-1 and Gal-3
as well as a variety of other molecules that were not found in
the larger vesicles. EVs from both fractions can be loaded with
anti-inflammatory drugs and pro-resolving mediators, either
alone or mixed, making possible the generation of particles with
cargoes containing a cocktail of molecules aimed at accelerating
inflammation resolution and improving the organ response
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to inflammation damage. Importantly, since incorporation of
PUFAs induces the generation of pro-inflammatory agents
in the EVs, which could interfere with the resolution of
inflammatory processes, these precursors should not be included
as cargo when planning a therapeutic intervention. Therefore,
altogether, these results provide support to the idea that EVs
from auditory HEI-OC1 cells could be useful nanocarriers
for the delivery of anti-inflammatory drugs and pro-resolving
mediators, but their cargo should be carefully tailored to
ensure that it will indeed promote the successful resolution of
inflammatory processes.
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